Interleukin 17 (IL-17) and its cognate receptor A (IL-17RA) play a crucial role in Th17 cells-mediated pro-inflammatory pathway and pathogenesis of several autoimmune disorders including psoriasis. IL-17 is mainly produced by activated Th-17 helper cells upon stimulation by IL-23 and, via binding to its receptors, mediates IL-17-driven cell signaling in keratinocytes. Hyper-proliferation of keratinocytes belongs to major clinical manifestations in psoriasis. To modulate IL-17-mediated inflammatory cascade, we generated a unique collection of IL-17RA-targeting protein binders that prevent from binding of human IL-17A cytokine to its cell-surface receptor. To this goal, we used a highly complex combinatorial library derived from scaffold of albumin-binding domain (ABD) of streptococcal protein G, and ribosome display selection, to yield a collection of ABD-derived high-affinity ligands of human IL-17RA, called ARS binders. From 67 analyzed ABD variants, 7 different sequence families were identified. Representatives of these groups competed with human IL-17A for binding to recombinant IL-17RA receptor as well as to IL-17RA-Immunoglobulin G chimera, as tested in enzyme-linked immunosorbent assay (ELISA). Five ARS variants bound to IL-17RA-expressing THP-1 cells and blocked binding of human IL-17 cytokine to the cell surface, as tested by flow cytometry. Three variants exhibited high-affinity binding with a nanomolar Kd value to human keratinocyte HaCaT cells, as measured using Ligand Tracer Green Line. Upon IL-17-stimulated activation, ARS variants inhibited secretion of Gro-α (CXCL1) by normal human skin fibroblasts in vitro. Thus, we identified a novel class of inhibitory ligands that might serve as immunosuppressive IL-17RA-targeted non-IgG protein antagonists.

Department of Dermatology and Venereology Faculty Hospital of Královské Vinohrady Šrobárova 50 100 34 Prague Czech Republic

Laboratory of Ligand Engineering Institute of Biotechnology of the Czech Academy of Sciences v v i BIOCEV Research Center Průmyslová 595 252 50 Vestec Czech Republic

Laboratory of Molecular Biology of the Bacterial Pathogens Institute of Microbiology Czech Academy of Sciences v v i Vídeňská 1083 142 20 Prague Czech Republic

Laboratory of Structural Bioinformatics of Proteins Institute of Biotechnology of the Czech Academy of Sciences v v i BIOCEV Research Center Průmyslová 595 252 50 Vestec Czech Republic

Zobrazit více v PubMed

Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–748. doi: 10.1038/nature01355. PubMed DOI

Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005;201:233–240. doi: 10.1084/jem.20041257. PubMed DOI PMC

Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463. doi: 10.1126/science.1135245. PubMed DOI PMC

Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725. doi: 10.1016/S1074-7613(00)00070-4. PubMed DOI

Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 2002;168:5699–5708. doi: 10.4049/jimmunol.168.11.5699. PubMed DOI

Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–651. doi: 10.1038/nature05505. PubMed DOI

Tang C., Chen S., Qian H., Huang W. Interleukin-23: As a drug target for autoimmune inflammatory diseases. Immunology. 2012;135:112–124. doi: 10.1111/j.1365-2567.2011.03522.x. PubMed DOI PMC

Dungan L.S., Mills K.H. Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. Cytokine. 2011;56:126–132. doi: 10.1016/j.cyto.2011.07.007. PubMed DOI

Song X., Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell. Signal. 2013;25:2335–2347. doi: 10.1016/j.cellsig.2013.07.021. PubMed DOI

Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34:149–162. doi: 10.1016/j.immuni.2011.02.012. PubMed DOI

Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010;10:248–256. doi: 10.1038/nri2742. PubMed DOI PMC

Sutton C.E., Mielke L.A., Mills K.H. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur. J. Immunol. 2012;42:2221–2231. doi: 10.1002/eji.201242569. PubMed DOI

Tonini A., Gualtieri B., Panduri S., Romanelli M., Chiricozzi A. A new class of biologic agents facing the therapeutic paradigm in psoriasis: Anti-IL-23 agents. Expert Opin. Biol. Ther. 2018;18:135–148. doi: 10.1080/14712598.2018.1398729. PubMed DOI

Papp K.A., Griffiths C.E., Gordon K., Lebwohl M., Szapary P.O., Wasfi Y., Chan D., Hsu M.C., Ho V., Ghislain P.D., et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up. Br. J. Dermatol. 2013;168:844–854. doi: 10.1111/bjd.12214. PubMed DOI

Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L.T., Gordon K.B. PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet. 2008;371:1665–1674. doi: 10.1016/S0140-6736(08)60725-4. PubMed DOI

Traczewski P., Rudnicka L. Briakinumab for the treatment of plaque psoriasis. BioDrugs. 2012;26:9–20. doi: 10.2165/11595940-000000000-00000. PubMed DOI

Gordon K.B., Langley R.G., Gottlieb A.B., Papp K.A., Krueger G.G., Strober B.E., Williams D.A., Gu Y., Valdes J.M. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Investig. Dermatol. 2012;132:304–314. doi: 10.1038/jid.2011.304. PubMed DOI

Reich K., Armstrong A.W., Foley P., Song M., Wasfi Y., Randazzo B., Li S., Shen Y.K., Gordon K.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J. Am. Acad. Dermatol. 2017;76:418–431. PubMed

Langley R.G., Tsai T.F., Flavin S., Song M., Randazzo B., Wasfi Y., Jiang J., Li S., Puig L. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial. Br. J. Dermatol. 2018;178:114–123. doi: 10.1111/bjd.15750. PubMed DOI

Papp K., Thaci D., Reich K., Riedl E., Langley R.G., Krueger J.G., Gottlieb A.B., Nakagawa H., Bowman E.P., Mehta A., et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br. J. Dermatol. 2015;173:930–939. doi: 10.1111/bjd.13932. PubMed DOI

Reich K., Papp K.A., Blauvelt A., Tyring S.K., Sinclair R., Thaci D., Nograles K., Mehta A., Cichanowitz N., Li Q., et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276–288. doi: 10.1016/S0140-6736(17)31279-5. PubMed DOI

Krueger J.G., Ferris L.K., Menter A., Wagner F., White A., Visvanathan S., Lalovic B., Aslanyan S., Wang E.E., Hall D., et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2015;136:116–124. doi: 10.1016/j.jaci.2015.01.018. PubMed DOI

Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., Antoni C., Draelos Z., Gold M.H., Psoriasis Study G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010;2:52ra72. doi: 10.1126/scitranslmed.3001107. PubMed DOI

Patel N.U., Vera N.C., Shealy E.R., Wetzel M., Feldman S.R. A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatol. Ther. 2017;4:233–246. doi: 10.1007/s40744-017-0076-0. PubMed DOI PMC

Lubrano E., Perrotta F.M. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther. Clin. Risk Manag. 2016;12:1587–1592. doi: 10.2147/TCRM.S100091. PubMed DOI PMC

Mease P.J., van der Heijde D., Ritchlin C.T., Okada M., Cuchacovich R.S., Shuler C.L., Lin C.Y., Braun D.K., Lee C.H., Gladman D.D., et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann. Rheum. Dis. 2017;76:79–87. PubMed PMC

Blair H.A. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs. 2018;78:495–504. doi: 10.1007/s40265-018-0888-4. PubMed DOI

Papp K.A., Gordon K.B., Langley R.G., Lebwohl M.G., Gottlieb A.B., Rastogi S., Pillai R., Israel R.J. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: Integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br. J. Dermatol. 2018;179:320–328. doi: 10.1111/bjd.16464. PubMed DOI

Zaretsky M., Etzyoni R., Kaye J., Sklair-Tavron L., Aharoni A. Directed evolution of a soluble human IL-17A receptor for the inhibition of psoriasis plaque formation in a mouse model. Chem. Biol. 2013;20:202–211. doi: 10.1016/j.chembiol.2012.11.012. PubMed DOI

Skrlec K., Strukelj B., Berlec A. Non-immunoglobulin scaffolds: A focus on their targets. Trends Biotechnol. 2015;33:408–418. doi: 10.1016/j.tibtech.2015.03.012. PubMed DOI

Martin H.L., Bedford R., Heseltine S.J., Tang A.A., Haza K.Z., Rao A., McPherson M.J., Tomlinson D.C. Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer. New Biotechnol. 2018;45:28–35. doi: 10.1016/j.nbt.2018.02.008. PubMed DOI

Ahmad J.N., Li J., Biedermannova L., Kuchar M., Sipova H., Semeradtova A., Cerny J., Petrokova H., Mikulecky P., Polinek J., et al. Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G. Proteins. 2012;80:774–789. doi: 10.1002/prot.23234. PubMed DOI

Nilvebrant J., Astrand M., Lofblom J., Hober S. Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. Cell. Mol. Life Sci. 2013;70:3973–3985. doi: 10.1007/s00018-013-1370-9. PubMed DOI PMC

Nilvebrant J., Hober S. The albumin-binding domain as a scaffold for protein engineering. Comput. Struct. Biotechnol. J. 2013;6:e201303009. doi: 10.5936/csbj.201303009. PubMed DOI PMC

Kuchar M., Vankova L., Petrokova H., Cerny J., Osicka R., Pelak O., Sipova H., Schneider B., Homola J., Sebo P., et al. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins. 2014;82:975–989. doi: 10.1002/prot.24472. PubMed DOI PMC

Mareckova L., Petrokova H., Osicka R., Kuchar M., Maly P. Novel binders derived from an albumin-binding domain scaffold targeting human prostate secretory protein 94 (PSP94) Protein Cell. 2015;6:774–779. doi: 10.1007/s13238-015-0194-9. PubMed DOI PMC

Zadravec P., Mareckova L., Petrokova H., Hodnik V., Perisic Nanut M., Anderluh G., Strukelj B., Maly P., Berlec A. Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit. PLoS ONE. 2016;11:e0162625. doi: 10.1371/journal.pone.0162625. PubMed DOI PMC

Krizova L., Kuchar M., Petrokova H., Osicka R., Hlavnickova M., Pelak O., Cerny J., Kalina T., Maly P. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells. Autoimmunity. 2017;50:102–113. doi: 10.1080/08916934.2016.1272598. PubMed DOI

Yao Z., Spriggs M.K., Derry J.M., Strockbine L., Park L.S., VandenBos T., Zappone J.D., Painter S.L., Armitage R.J. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine. 1997;9:794–800. doi: 10.1006/cyto.1997.0240. PubMed DOI

Cho K.A., Suh J.W., Lee K.H., Kang J.L., Woo S.Y. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1beta by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 2012;24:147–158. doi: 10.1093/intimm/dxr110. PubMed DOI

Goetsch L., Haeuw J.F., Champion T., Lacheny C., N’Guyen T., Beck A., Corvaia N. Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148. Clin. Diagn. Lab. Immunol. 2003;10:125–132. doi: 10.1128/CDLI.10.1.125-132.2003. PubMed DOI PMC

Liu S., Song X., Chrunyk B.A., Shanker S., Hoth L.R., Marr E.S., Griffor M.C. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat. Commun. 2013;4:1888. doi: 10.1038/ncomms2880. PubMed DOI

Sarra M., Pallone F., Macdonald T.T., Monteleone G. IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 2010;16:1808–1813. doi: 10.1002/ibd.21248. PubMed DOI

West N.R., McCuaig S., Franchini F., Powrie F. Emerging cytokine networks in colorectal cancer. Nat. Rev. Immunol. 2015;15:615–629. doi: 10.1038/nri3896. PubMed DOI

Skrlec K., Zadravec P., Hlavnickova M., Kuchar M., Vankova L., Petrokova H., Krizova L., Cerny J., Berlec A., Maly P. p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin. Int. J. Mol. Sci. 2018;19:1933. doi: 10.3390/ijms19071933. PubMed DOI PMC

Schetter A.J., Nguyen G.H., Bowman E.D., Mathe E.A., Yuen S.T., Hawkes J.E., Croce C.M., Leung S.Y., Harris C.C. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin. Cancer Res. 2009;15:5878–5887. doi: 10.1158/1078-0432.CCR-09-0627. PubMed DOI PMC

Wang L., Yi T., Zhang W., Pardoll D.M., Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 2010;70:10112–10120. doi: 10.1158/0008-5472.CAN-10-0775. PubMed DOI PMC

He D., Li H., Yusuf N., Elmets C.A., Athar M., Katiyar S.K., Xu H. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE. 2012;7:e32126. doi: 10.1371/journal.pone.0032126. PubMed DOI PMC

Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993;234:779–815. doi: 10.1006/jmbi.1993.1626. PubMed DOI

Johansson M.U., Frick I.M., Nilsson H., Kraulis P.J., Hober S., Jonasson P., Linhult M., Nygren P.A., Uhlen M., Bjorck L., et al. Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J. Biol. Chem. 2002;277:8114–8120. doi: 10.1074/jbc.M109943200. PubMed DOI

Sievers F., Wilm A., Dineen D., Gibson T.J., Karplus K., Li W., Lopez R., McWilliam H., Remmert M., Soding J., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011;7:539. doi: 10.1038/msb.2011.75. PubMed DOI PMC

Kozakov D., Beglov D., Bohnuud T., Mottarella S.E., Xia B., Hall D.R., Vajda S. How good is automated protein docking? Proteins. 2013;81:2159–2166. doi: 10.1002/prot.24403. PubMed DOI PMC

Kozakov D., Brenke R., Comeau S.R., Vajda S. PIPER: An FFT-based protein docking program with pairwise potentials. Proteins. 2006;65:392–406. doi: 10.1002/prot.21117. PubMed DOI

Eastman P., Pande V.S. OpenMM: A Hardware Independent Framework for Molecular Simulations. Comput. Sci. Eng. 2015;12:34–39. doi: 10.1109/MCSE.2010.27. PubMed DOI PMC

Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A.E., Berendsen H.J. GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005;26:1701–1718. doi: 10.1002/jcc.20291. PubMed DOI

Human IL-22 receptor-targeted small protein antagonist suppress murine DSS-induced colitis

Small protein blockers of human IL-6 receptor alpha inhibit proliferation and migration of cancer cells

Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice

Targeting Human Thrombus by Liposomes Modified with Anti-Fibrin Protein Binders

Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice

Engineered Lactococcus lactis Secreting IL-23 Receptor-Targeted REX Protein Blockers for Modulation of IL-23/Th17-Mediated Inflammation